Bladder Cancer Specialist Hamlet Pharma Secures FDA Phase III Nod, Inks LOI for Global Alpha1H Deal

Swedish biotech Hamlet BioPharma reports quarterly results on May 22 with FDA-approved Phase III trial design for Alpha1H, targeting a €4.9B bladder cancer market and 80% recurrence rate. Cash runway, partnership deals in focus.

Hamlet BioPharma is heading into its quarterly report on May 22 with more than just cash burn on investors’ minds. The Swedish biotech has stacked up a series of milestones since February, capped by a green light from the US Food and Drug Administration for the pivotal Phase III trial design of its lead asset, Alpha1H.

The FDA’s sign-off came with clearly defined endpoints — complete response rate and event?free survival — and builds on compelling Phase II data. In that mid?stage study, the high?dose group saw an average tumour shrinkage of 59%, an overall response rate of 80% and no severe adverse events. Alpha1H, which attacks cancer cells locally in the bladder, already holds Fast?Track designation from the agency for non?muscle invasive bladder cancer, speeding the path to approval. Patient recruitment can start as soon as ethics committees give the nod.

A €4.9?billion market with an 80% recurrence problem

The commercial rationale is hard to ignore. Bladder cancer ranks among the costliest malignancies per patient, with total European healthcare costs exceeding €4.9?billion annually. Up to 80% of patients relapse after initial surgery if therapy is suboptimal, creating a clear need for better neoadjuvant options. Hamlet is targeting exactly that niche: Alpha1H would be used first as a pre?operative treatment.

Management has already signed a non?binding letter of intent with an unnamed uro?oncology specialist based in northern Germany to complete clinical development and handle worldwide marketing. A final agreement is still subject to legal and financial due diligence. To ensure terms meet international standards, Hamlet has brought in PharmaVentures, a consultancy focused on pharma licensing, to advise on the negotiations. Multiple other potential partners are also in talks.

Financial transparency on the horizon

The coming interim report will reveal how long the company’s cash reserves can sustain operations. The market is hoping for concrete updates on the German negotiations and a precise timeline for the Phase III launch. On the technical side, the stock closed at SEK?7.12 on May?13, having slipped below a short?term support level. The next floor is seen at SEK?6.00, with resistance at SEK?8.80, within a medium?term upward trend channel.

Pipeline breadth beyond oncology

Hamlet is not a one?asset story. In February?2026 — still within its current financial year — it struck a collaboration with South Korea’s ImmunoForge to develop new delivery technologies for the peptide drug NZX, which targets lung tuberculosis. The programme has shown promise against resistant bacterial strains in animal models. Separately, the IL?1 inhibitor Anakinra has demonstrated efficacy against recurrent urinary tract infections, cutting pain and relapse rates to levels comparable with antibiotics. In total, the pipeline holds 15 projects, all with proof of concept in animal models.

The patent portfolio, comprising 147 granted patents and 33 pending applications, provides a substantial barrier to entry for any would?be competitor and strengthens Hamlet’s hand at the negotiating table.

All eyes now turn to May?22. If the quarterly numbers show a healthy cash runway alongside progress on the Alpha1H partnering process, the stock could find fresh momentum.